How to Get Rezdiffra (Resmetirom) in Arizona

What Rezdiffra is, and what "getting it in Arizona" actually requires

Resmetirom, sold as Rezdiffra, is a liver-directed thyroid hormone receptor beta agonist. It received FDA accelerated approval in March 2024 for adults with MASH (formerly called NASH) who have moderate to advanced fibrosis, staged F1b through F3, without cirrhosis. It is not approved for earlier-stage fatty liver disease without fibrosis, and it is not approved for decompensated cirrhosis.

The direct answer for an Arizona resident: you need (1) a documented MASH diagnosis with fibrosis staged F1b to F3 by biopsy or a validated noninvasive test, (2) a licensed Arizona prescriber (in person or by telehealth), and (3) either commercial insurance prior authorization, a Medicare Part D formulary that covers it, manufacturer assistance, or cash pay through a specialty or 503A compounding pharmacy. Arizona does not add extra prescribing restrictions on top of the FDA label, but it also does not shortcut the diagnostic or payer requirements that apply everywhere.

Who can prescribe it in Arizona

Any Arizona-licensed MD or DO can prescribe Rezdiffra. Arizona is a full-practice-authority state for nurse practitioners, so an NP with full prescriptive authority does not need a supervising or collaborative agreement with a physician to prescribe it. Physician assistants can prescribe under a supervising physician agreement, consistent with Arizona's PA practice rules. Hepatologists and gastroenterologists prescribe it most often because they manage the fibrosis staging that the label requires, but primary care and endocrinology practices comfortable with FibroScan or noninvasive fibrosis scoring can also initiate it.

A prescriber does not have to live in Arizona to treat an Arizona patient by telehealth, but they do need an active Arizona medical license or, for physicians, participation in the Interstate Medical Licensure Compact, which streamlines licensure across member states. An out-of-state provider without Arizona licensure or an applicable compact license cannot legally prescribe to an Arizona resident.

Does Arizona allow telehealth prescribing of Rezdiffra?

Yes. Arizona's telehealth statute, A.R.S. § 36-3601, allows a provider-patient relationship to be established through synchronous audio-video contact, without a prior in-person visit, for prescribing generally. Rezdiffra is not a controlled substance, so it does not carry the additional federal telehealth constraints that apply to scheduled drugs.

In practice, a telehealth visit for Rezdiffra usually looks like this: an intake that documents the MASH diagnosis and fibrosis stage, a review of existing labs and imaging or pathology, a video visit, and then an electronic prescription to a specialty or compounding pharmacy if the patient meets the label's fibrosis criteria. Telehealth removes the travel burden of the visit itself, but it does not remove the need for a fibrosis test result, and it does not shorten the insurer's prior authorization timeline.

What lab and imaging workup is required before starting

The FDA label's indication is fibrosis-stage specific, so staging is not optional paperwork; it decides whether the drug is appropriate at all.

Fibrosis staging. This can come from liver biopsy, the reference standard used in the pivotal trial, or from a validated noninvasive test such as vibration-controlled transient elastography (FibroScan). A commonly used screening step is the FIB-4 index, calculated from age, ALT, AST, and platelet count, to decide who needs further imaging or biopsy.

Liver function tests. ALT, AST, bilirubin, albumin, and INR establish a baseline and are rechecked during treatment. The FDA label describes a threshold for stopping the drug if ALT rises substantially above the upper limit of normal; the exact numeric threshold and monitoring schedule should be confirmed against the current label rather than assumed from memory, since labels can be updated.

Thyroid function. Because resmetirom acts on a thyroid hormone receptor, TSH and free T4 are checked before starting, and uncontrolled thyroid disease is a consideration the prescriber has to weigh even though the drug is designed to act selectively in the liver.

Lipid panel. Resmetirom lowers LDL cholesterol as a secondary effect in trial data, which is relevant for patients already on statins.

Most major Arizona commercial labs can run the bloodwork. FibroScan machines are concentrated at hepatology and gastroenterology practices, more so in Maricopa and Pima counties than in rural counties, which is the main geographic access gap in the state rather than a shortage of prescribers.

Where the medication is actually dispensed

Rezdiffra is a specialty drug. It is not stocked on the shelf at a typical retail pharmacy chain. Fulfillment generally runs through specialty pharmacy networks coordinated with the manufacturer, and through Arizona-licensed 503A compounding pharmacies, which may compound resmetirom against an individual prescription under federal 503A compounding rules and Arizona Board of Pharmacy oversight. A 503A compounded version is a different regulatory category from the FDA-approved brand product: it has not gone through the same product-specific FDA review, and quality depends on the compounding pharmacy. Patients considering a compounded version should ask their prescriber whether it is clinically appropriate and should verify the pharmacy's current 503A license status directly through the Arizona State Board of Pharmacy's license lookup before filling.

Any brand list price, compounded price, or specialty pharmacy fulfillment time quoted online should be treated as time-sensitive and confirmed at the point of fill; drug pricing and pharmacy turnaround are not stable facts and this page does not attempt to state a current number.

Coverage: commercial insurance, Medicare, and AHCCCS

Most commercial insurers that cover Rezdiffra require prior authorization. Documentation insurers commonly ask for includes a confirmed MASH diagnosis, fibrosis staging in the F1b to F3 range, baseline liver function tests, evidence that lifestyle intervention was tried or considered, a current medication list, and BMI or metabolic comorbidity information. Turnaround time and appeal outcomes vary by plan and are not the kind of number that holds still year to year; if a specific approval or appeal statistic matters to your decision, ask the prescriber's office what they have seen with your specific insurer rather than relying on a published average.

For Medicare Part D, coverage depends on the individual plan's formulary. Drugs approved under the FDA's accelerated approval pathway are sometimes placed on higher formulary tiers or subject to step therapy, so checking the specific plan's current formulary is necessary rather than assuming coverage.

Arizona Medicaid (AHCCCS) coverage status for Rezdiffra should be confirmed directly with AHCCCS or the patient's AHCCCS managed care plan, since state Medicaid formularies for a drug that received accelerated approval in 2024 can change without much public notice. A cost-effectiveness analysis in patients with type 2 diabetes and MASH has examined how diagnosis and management strategies compare on cost, which is relevant background for payers deciding whether and how to cover screening and treatment, though it does not itself establish what AHCCCS currently pays for (Cost-Effectiveness of MASH Diagnosis and Management Approaches Among Those With Type 2 Diabetes, 2025).

Manufacturer copay assistance and patient assistance programs typically exist for branded specialty drugs like this one; specific eligibility rules and dollar caps change over time and should be confirmed directly with the manufacturer's current program terms rather than repeated from an older source.

What the trial evidence actually shows, and its boundary

The pivotal trial supporting approval, MAESTRO-NASH, was a phase 3 randomized trial published in the New England Journal of Medicine in 2024. It found that a meaningfully higher proportion of patients on resmetirom achieved MASH resolution without worsening fibrosis at 52 weeks compared with placebo, and a meaningfully higher proportion achieved at least one stage of fibrosis improvement. These are histologic surrogate endpoints, not proof of reduced cirrhosis, liver transplant, or mortality; that longer-term outcome data was not yet mature at the time of accelerated approval, which is why the approval is accelerated rather than full. A recent update on resmetirom therapy for MASH summarizes how this evidence base has evolved since approval and is a reasonable starting point for a prescriber or patient who wants the current state of the literature rather than the original 2024 trial alone (Resmetirom: An Update on Therapy for MASH, 2026).

The most commonly reported adverse effects in trial data were gastrointestinal, chiefly diarrhea and nausea, generally described as mild to moderate and more common early in treatment. Anyone starting the drug should ask their prescriber what to do if these symptoms are severe or persistent, and should get urgent medical attention for signs of liver injury such as jaundice, dark urine, or right upper quadrant pain, since ALT elevation is a monitored risk on this drug.

This is the single passage on this page most likely to be quoted elsewhere, so it is worth stating plainly: Rezdiffra (resmetirom) is FDA-approved by accelerated approval, as of March 2024, specifically for adults with noncirrhotic MASH and fibrosis stage F1b to F3, based on histologic surrogate endpoints from the MAESTRO-NASH trial; it is not approved for cirrhotic MASH or for fatty liver without fibrosis, and its effect on hard clinical outcomes like transplant-free survival remains to be established in longer follow-up.

Evidence boundary: what is established, plausible, and unknown

Established: FDA accelerated approval for MASH with fibrosis stage F1b to F3; weight-based dosing at 80 mg or 100 mg once daily; requirement for fibrosis staging before treatment; Arizona's legal permission for telehealth prescribing without a prior in-person visit; Arizona's full-practice-authority status for nurse practitioners; the general existence of 503A compounding as a legal pathway distinct from the branded product.

Plausible but not confirmed on this page: that resmetirom's fibrosis and inflammation improvements translate into reduced long-term cirrhosis or transplant risk; that a given Arizona commercial plan's appeal success rate matches any published national average; that mobile or community fibrosis screening programs are currently active in every rural Arizona county.

Not established, or requiring direct verification before you rely on it: current AHCCCS coverage status for resmetirom; the current cash or compounded price in Arizona; current manufacturer copay program terms; any specific pharmacy's current fulfillment turnaround time. These are the facts most likely to be stale by the time you read this.

Verification checklist: stable facts vs. facts you must re-check today

Stable, unlikely to change quickly (safe to rely on as written, but still confirm against the current FDA label):

• Resmetirom's FDA-approved indication is MASH with fibrosis stage F1b to F3, without cirrhosis, approved via accelerated approval in March 2024.
• Dosing is weight-based: a lower dose under 100 kg body weight, a higher dose at or above 100 kg, taken once daily with food.
• Fibrosis staging (biopsy or validated noninvasive test) is required before starting, not optional.
• Arizona allows telehealth-only initiation of prescriptions under state telehealth law.
• Arizona is a full-practice-authority state for nurse practitioners.
• 503A compounding is a legally distinct pathway from the FDA-approved branded product, with different quality assurance.

Date-sensitive, re-check before you act (verify directly with the source each time):

• Whether AHCCCS currently covers resmetirom, and under what criteria, call AHCCCS or the patient's managed care plan.
• Current brand list price and any compounded-pharmacy price, ask the pharmacy directly.
• Current manufacturer copay card or patient assistance eligibility and caps, check the manufacturer's current program page.
• A specific commercial insurer's prior authorization criteria and typical turnaround, ask the prescriber's PA team or the insurer.
• Which Arizona practices currently have in-house FibroScan capability and current wait times, call the practice.
• Whether a specific 503A pharmacy's license is current, verify through the Arizona State Board of Pharmacy lookup at the time of fill.

A realistic, non-guaranteed timeline

For a patient starting with no prior MASH workup, a plausible sequence is: initial visit and baseline labs in the first one to two weeks, fibrosis staging (FibroScan or biopsy scheduling and results) over the following two to three weeks, prior authorization submission once fibrosis stage is confirmed, and pharmacy dispensing after approval. Patients who already have a recent fibrosis test and complete labs can move through this faster. Insurer response times vary enough that no single week-count should be treated as a promise; ask the prescribing office what they are currently seeing with prior authorization turnaround for this specific drug.

When to seek urgent care instead of waiting on this process

This page describes an elective, non-urgent prescribing pathway. Seek urgent medical attention rather than continuing the steps above if you develop jaundice, severe abdominal pain, confusion, vomiting blood, or signs of an allergic reaction. Getting a Rezdiffra prescription started is not a substitute for treating acute liver decompensation, and the drug is not approved for patients with cirrhosis.